Sanofi announces Fovea takeover, licensing deal with Merrimack

10/1/2009 | Reuters · MarketWatch

Sanofi-Aventis purchased Fovea Pharmaceuticals, a biotech firm that specializes in eye treatments, for as much as $542 million. In a separate deal, Sanofi agreed to pay $60 million upfront to further develop Merrimack Pharmaceuticals' MM-121 monoclonal antibody for solid tumors.

View Full Article in:

Reuters · MarketWatch